According to some Finnish researchers, children with heterozygous familia hypercholesterolemia (HeFH) should use statins as a treatment with caution. Though they have proven to be able to lower lipid levels in HeFH patients, it is still important to be careful about it.
Led by researcher Vuorio, the team carried out an analysis of nine randomized placebo-controlled trials, receiving follow up anytime between six weeks to two years.
When results came, the news was pretty good. Statins were shown to reduce the average low-density lipoprotein (LDL) cholesterol concentration at every time checkpoints, but some concentrations did not see significant differences in the placebo versus the treated groups.
In addition, the risks of clinical adverse effects, such as myopathy, were similar and low in both the placebo and treated groups.
Often times, diagnosis of HeFH is measured by either high total cholesterol and LDL cholesterol levels or by DNA-based analysis. Sometimes, both are used to diagnose the condition.